Clinical pathway

Cardio-Oncology Scores

A focused collection of 20 calculators, scores, and clinical references.

20tools & references

Interactive worksheet

BNP Elevation Risk Tier (Cardiotoxicity Marker) Calculator

BNP Elevation Risk Tier (Cardiotoxicity Marker): Explanation and Clinical Context B-type Natriuretic Peptide (BNP) is a cardiac neurohormone released in response to ventricular volume expansion and pressure overload. Elevated BNP levels in patients undergoing potentially cardiotoxic therapies, such as anthracyclines or trastuzumab, may indicate early myocardial stress and subclinical cardiotoxicity. BNP risk stratifi

Interactive worksheet

Breast Cancer Adjuvant Therapy Cardiac Risk Stratification

: Explanation and Clinical Context This tool estimates the risk of developing cardiotoxicity in breast cancer patients receiving adjuvant therapy, particularly with anthracyclines and/or trastuzumab. Risk factors include advanced age, lower baseline left ventricular ejection fraction (LVEF), presence of hypertension or diabetes, and exposure to cardiotoxic agents. The calculated risk score stratifies patients into Lo

Interactive worksheet

Cardiotoxicity Risk by Troponin (TnI, TnT) Calculator

Cardiotoxicity Risk by Troponin: Explanation and Clinical Context The Cardiotoxicity Risk Calculator estimates the likelihood of developing chemotherapy-induced cardiac dysfunction based on Troponin I (TnI) and Troponin T (TnT) levels. Elevated troponin levels during or shortly after chemotherapy are predictive of subsequent left ventricular dysfunction and heart failure. Troponin I <0.04 ng/mL is generally associate

Interactive worksheet

CHOP/Anthracycline Cumulative Dose Score Calculator

CHOP/Anthracycline Cumulative Dose Score: Explanation and Clinical Context The CHOP/Anthracycline Cumulative Dose Score estimates the risk of anthracycline-induced cardiotoxicity by calculating the total doxorubicin-equivalent dose from different anthracycline drugs, including doxorubicin, daunorubicin, and epirubicin. Conversion factors are applied to account for differences in cardiotoxic potential: daunorubicin ×

Interactive worksheet

Cleveland Clinic Anthracycline-Induced Heart Failure Risk Calculator

: Explanation and Clinical Context This tool estimates the risk of developing heart failure following anthracycline chemotherapy based on key clinical factors. It incorporates the cumulative dose of doxorubicin, patient age, and the presence of hypertension, diabetes mellitus, and smoking history. A higher risk score indicates a greater likelihood of cardiotoxicity, guiding clinicians in monitoring and preventive str

Interactive worksheet

ESC Immunotherapy-Related Myocarditis Score Calculator

ESC Immunotherapy-Related Myocarditis Score: Explanation and Clinical Context The ESC Immunotherapy-Related Myocarditis Score is a prognostic tool developed to assess the risk of severe outcomes in patients with immune checkpoint inhibitor (ICI)-associated myocarditis. This score incorporates five key clinical parameters: presence of active thymoma, cardiomyositis symptoms, low QRS voltage on ECG, left ventricular ej

Interactive worksheet

ESMO Anthracycline Risk Category Calculator

ESMO Anthracycline Risk Category: Explanation and Clinical Context The ESMO Anthracycline Risk Category is a stratification tool developed to assess the risk of cardiovascular toxicity in patients undergoing anthracycline-based chemotherapy. This tool considers factors such as age, sex, pre-existing cardiovascular disease, and cumulative anthracycline dose to categorize patients into low, moderate, or high-risk group

Interactive worksheet

Global Longitudinal Strain Early Change Index (GLS-ECI) Calculator

Global Longitudinal Strain Early Change Index (GLS-ECI): Explanation and Clinical Context The Global Longitudinal Strain Early Change Index (GLS-ECI) is a sensitive echocardiographic measure used to detect early myocardial dysfunction before overt changes in left ventricular ejection fraction occur. It is calculated as the percentage change between baseline GLS and follow-up GLS: GLS-ECI (%) = (Follow-up GLS − Baseli

Interactive worksheet

HER2 Therapy Cardiotoxicity Index (Trastuzumab) Calculator

HER2 Therapy Cardiotoxicity Index (Trastuzumab): Explanation and Clinical Context Trastuzumab, a monoclonal antibody targeting the HER2 receptor, is widely used in the treatment of HER2-positive breast cancer. However, its use is associated with an increased risk of cardiotoxicity, particularly in patients with pre-existing cardiovascular conditions, older age, prior anthracycline therapy, and elevated body mass inde

Interactive worksheet

HFA-ICOS Cardio-Oncology Risk Score Calculator

HFA-ICOS Cardio-Oncology Risk Score (ESC 2022): Explanation and Clinical Context The HFA-ICOS Cardio-Oncology Risk Score is designed to stratify patients based on their baseline cardiovascular risk when initiating potentially cardiotoxic cancer therapy. The score incorporates patient-specific factors including age, sex, hypertension, diabetes, prior heart failure or cardiomyopathy, previous cardiovascular disease, an

Interactive worksheet

HFA-ICOS Dynamic Surveillance Index Calculator

HFA-ICOS Dynamic Surveillance Index: Explanation and Clinical Context The HFA-ICOS Dynamic Surveillance Index is a risk stratification tool developed by the Heart Failure Association of the European Society of Cardiology and the International Cardio-Oncology Society. It is designed to assess the cardiovascular risk in oncology patients prior to initiating potentially cardiotoxic anti-cancer therapies. The index consi

Interactive worksheet

ICOS Biomarker Model Calculator

ICOS Biomarker Model: Explanation and Clinical Context The ICOS Biomarker Model integrates cardiac biomarkers and echocardiographic parameters to assess the risk of cardiotoxicity in cancer patients. Elevated levels of troponin (>16 ng/L) and BNP (>100 pg/mL), along with a reduced global longitudinal strain (<-18%), are indicative of increased risk. This model aids clinicians in early identification and management of

Interactive worksheet

Immune Checkpoint Inhibitor Myocarditis Risk Index Calculator

Immune Checkpoint Inhibitor Myocarditis Risk Index: Explanation and Clinical Context This risk index is derived from a multicenter study involving 748 patients treated with immune checkpoint inhibitors (ICIs). The index incorporates five key factors: presence of active thymoma, cardio-muscular symptoms, low QRS voltage on electrocardiogram, left ventricular ejection fraction (LVEF) <50%, and elevated troponin levels.

Interactive worksheet

LV GLS Drop >15% Calculator

LV GLS Drop >15% Rule: Explanation and Clinical Context The LV GLS (Left Ventricular Global Longitudinal Strain) Drop >15% Rule is used for early detection of subclinical cardiotoxicity, particularly in patients receiving potentially cardiotoxic chemotherapy, such as anthracyclines or trastuzumab. GLS is a sensitive echocardiographic parameter reflecting myocardial deformation. A relative reduction of more than 15% f

Interactive worksheet

LVEF Decline Hazard Ratio Calculator

LVEF Decline Hazard Ratio Model: Explanation and Clinical Context Left ventricular ejection fraction (LVEF) decline is a significant predictor of adverse outcomes in heart failure patients. A decline of > 5% in LVEF is associated with a 2.2-fold increased risk of mortality. This model assists clinicians in identifying patients at higher risk due to LVEF deterioration, enabling timely interventions and management stra

Interactive worksheet

Mayo Clinic Cardiotoxicity Risk Score Calculator

Mayo Clinic Cardiotoxicity Risk Score: Explanation and Clinical Context The Mayo Clinic Cardiotoxicity Risk Score is a clinical tool designed to predict the risk of cardiotoxicity in cancer patients undergoing chemotherapy, particularly those treated with anthracyclines. This score integrates various patient-related risk factors, including age, gender, and the presence of cardiovascular comorbidities, to stratify pat

Interactive worksheet

Mean Heart Dose (MHD) Risk Predictor

: Explanation and Clinical Context The Mean Heart Dose (MHD) is a critical metric in radiation therapy, especially for patients undergoing treatment for left-sided breast cancer. Studies have shown a linear relationship between MHD and the risk of subsequent major cardiac events, with a 7.4% relative increase per 1 Gy of MHD. This means that for every gray (Gy) increase in MHD, the risk of cardiac events increases by

Interactive worksheet

Pericardial Radiation Risk Calculator

Pericardial Radiation Risk Model: Explanation and Clinical Context The Pericardial Radiation Risk Model estimates the risk of pericardial complications based on the patient's age at the time of radiation exposure and the dose received by the pericardium. This model is crucial for assessing long-term cardiovascular risks in patients who have undergone mediastinal radiation therapy. Understanding these risks aids clini

Interactive worksheet

Radiation-Induced Heart Disease (RIHD) Dose Index Calculator

Radiation-Induced Heart Disease (RIHD) Dose Index: Explanation and Clinical Context RIHD Dose Index (RIHD-DI) is a predictive measure used to estimate the risk of cardiac complications in patients receiving thoracic radiotherapy. The index incorporates key dosimetric parameters: Mean Heart Dose, Maximum Heart Dose, and the percentage of heart volume receiving >25 Gy (V25). This model is based on epidemiological and c

Interactive worksheet

Valvular Dysfunction Radiation Index (VDRI) Calculator

Valvular Dysfunction Radiation Index (VDRI): Explanation and Clinical Context The VDRI is a predictive model developed to estimate the risk of radiation-induced valvular heart disease (RVD). It incorporates key factors known to influence the development of RVD, including: - Age at Radiation Exposure: Younger age at the time of radiation therapy is associated with a higher risk of developing RVD later in life. - Radia